Mein Warenkorb

CD45RO

CD45RO Molekülinformation

Englischer NameLeukocyte common antigenAnzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel7Target-AliasPTPRC,T200,CD45,Protein Tyrosine Phosphatase, Receptor Type C,CD45 Antigen,L-CA,Protein Tyrosine Phosphatase, Receptor Type, C Polypeptide,Receptor-Type Tyrosine-Protein Phosphatase C,T200 Leukocyte Common Antigen,Leukocyte Common Antigen,T200 Glycoprotein,EC 3.1.3.48,CD45R,GP180,B220,LCA,LY5,Leukocyte Common Antigens,Protein Tyrosine Phosphatase Receptor Type C,EC:3.1.3.48
Höchste Forschungs- und EntwicklungsphasePhase 3 Clinical
Englischer NameLeukocyte common antigen
Target-AliasPTPRC,T200,CD45,Protein Tyrosine Phosphatase, Receptor Type C,CD45 Antigen,L-CA,Protein Tyrosine Phosphatase, Receptor Type, C Polypeptide,Receptor-Type Tyrosine-Protein Phosphatase C,T200 Leukocyte Common Antigen,Leukocyte Common Antigen,T200 Glycoprotein,EC 3.1.3.48,CD45R,GP180,B220,LCA,LY5,Leukocyte Common Antigens,Protein Tyrosine Phosphatase Receptor Type C,EC:3.1.3.48
Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel7
Höchste Forschungs- und EntwicklungsphasePhase 3 Clinical

CD45RO Produktliste

  • Attribut

    Antibody (2)Protein (1)

  • Produktbibliothek

    Online (3)

  • Spezies

    Mouse (2)Human (1)

  • Etikett

    - (2)His Tag (1)

  • Marker

    Unconjugated (2)PE Labeled (1)

CD45RO Molekülalias

B220, CD45, CD45R, GP180, IMD105, L-CA, LCA, LY5, T200

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
Immunomodulatory progenitor cell therapy (Celixir)Phase 3 ClinicalCelixirCardiomyopathies; Endomyocardial Fibrosis
Details
I-131-ApamistamabBC8-I-131; BC-8; 131IBC8; I-131 BC-8Phase 3 ClinicalFred Hutchinson Cancer Research CenterAnemia, Refractory, with Excess of Blasts; Anemia, Sickle Cell; Anemia, Sideroblastic; Angioimmunoblastic T-cell Lymphoma; Burkitt Lymphoma; Graft vs Host Disease; Hematopoietic stem cell transplantation (HSCT); Hodgkin Disease; Intraocular Lymphoma; Leukemia; Leukemia, Hairy Cell; Leukemia, Large Granular Lymphocytic; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Leukemia-Lymphoma, Adult T-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Lymphomatoid Granulomatosis; Mycosis Fungoides; Myelodysplastic Syndromes; Neoplasms, Gonadal Tissue; Neoplastic Cells, Circulating; Pancytopenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sezary Syndro
Details
At 211 MAb BC8-B10Phase 2 ClinicalFred Hutchinson Cancer Research CenterNeoplasms
Details
211At-BC8-B10211At-BC8-B10Phase 2 ClinicalFred Hutchinson Cancer Research Center, National Cancer InstituteHematologic Neoplasms; Leukemia; Leukemia, Biphenotypic, Acute; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Lymphoma; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma
Details
CD45BE-HSPC cells therapy (Kite Pharma)Phase 1 ClinicalKite PharmaHodgkin Disease; Lymphoma, B-Cell; Lymphoma, T-Cell; Richter's Syndrome
Details
CART-45 cells therapy (Kite Pharma)Phase 1 ClinicalKite PharmaHodgkin Disease; Lymphoma, B-Cell; Lymphoma, T-Cell; Richter's Syndrome
Details
TSC-102TSC-102-A03; TSC-102-A0301; TSC-102; TSC-102-A01Phase 1 ClinicalTScan Therapeutics IncHematologic Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma
Details
  • Molekülinformation
  • Produktliste
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns